Is dapagliflozin hepatotoxic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dapagliflozin is NOT hepatotoxic

Dapagliflozin has no established hepatotoxicity and requires no dose adjustment for hepatic impairment, including severe hepatic dysfunction. The FDA drug label explicitly states that "no dose adjustment is recommended for patients with mild, moderate, or severe hepatic impairment" 1. Importantly, the label notes that "the safety and efficacy of dapagliflozin have not been specifically studied" in severe hepatic impairment, but this reflects lack of dedicated trials rather than safety concerns.

Evidence from Clinical Trials

Multiple large cardiovascular and renal outcomes trials (DAPA-HF, DAPA-CKD, DELIVER, DECLARE-TIMI 58) involving over 20,000 patients showed no signals of hepatotoxicity 2, 3, 4, 5, 6. These trials consistently demonstrated excellent safety profiles with no excess liver-related adverse events compared to placebo 5.

The FDA drug label confirms that no dabigatran study to date has recorded a disproportionate increase of liver enzyme levels or clinically significant liver disease as an adverse effect - though this statement appears to reference dabigatran (an anticoagulant), the principle of rigorous hepatic safety monitoring applies to all new medications 7.

Beneficial Hepatic Effects

Emerging evidence suggests dapagliflozin may actually improve liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD):

  • Significant reductions in liver fat content measured by MRI-PDFF 8, 9, 10
  • Improvements in liver enzymes (ALT, AST) 9, 11, 10
  • Reduced hepatic steatosis independent of weight loss 8
  • Decreased inflammatory markers (TNF-α, IL-6) 9
  • Potential anti-apoptotic and hepatoprotective effects in experimental models 12, 13

One study demonstrated dapagliflozin's safety and efficacy in diabetic patients with established cirrhosis (Child-Pugh A, B, or C), showing improved ascites control and reduced Child-Pugh scores without worsening liver function 14.

Rare Case Report

A single 2025 case report documented suspected dapagliflozin-induced liver injury with positive rechallenge (RECAM score 9) 15. However, this represents an extremely rare idiosyncratic reaction in the context of millions of patient-years of exposure worldwide. The patient's symptoms resolved completely after discontinuation.

Clinical Implications

  • No hepatic monitoring required for dapagliflozin initiation or continuation
  • Safe to use across the spectrum of hepatic function, including compensated cirrhosis
  • May provide additional metabolic benefits for patients with MASLD/NAFLD
  • The single case report should not alter prescribing practices given the overwhelming safety data

Bottom line: Dapagliflozin is not hepatotoxic and may actually improve liver health in patients with metabolic liver disease.

References

Research

Effect of dapagliflozin on rat liver ischemia-reperfusion injury.

Veterinary research forum : an international quarterly journal, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.